CFO of Iveda Solutions (IVDA) reports 125,000-option repricing and net 152,503 held

Rhea-AI Filing Summary

Iveda Solutions Chief Financial Officer Robert J. Brilon reported changes to his stock options in a paired, non-cash transaction. He was granted 125,000 options and disposed of 125,000 options, both recorded as “Options (Right to Buy).” Following these transactions, he holds 152,503 derivative securities directly.

The company’s board approved an option repricing on February 23, 2026, resetting the exercise price of his options to $0.29 per share. The filing states that all other option terms remain unchanged and that the repricing was exempt under specific Exchange Act rules.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BRILON ROBERT J

(Last) (First) (Middle)

1744 S. VAL VISTA DRIVE,

STE. 213

(Street)

MESA AZ 85204

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Iveda Solutions, Inc. [ IVDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$0.82	12/29/2025		D		125,000		12/29/2025	12/29/2035	Common Stock	125,000	$0.00	152,503	D
Options (Right to Buy)	$0.29(1)	02/23/2026		A		125,000		12/29/2025	12/29/2035	Common Stock	125,000	$0.00	152,503	D

Explanation of Responses:

1. On February 23, 2026, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $0.29 per share. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

	/s/ Robert J Brilon	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Iveda Solutions (IVDA) report in this Form 4?

The Form 4 reports that Iveda Solutions’ CFO, Robert J. Brilon, both acquired and disposed of 125,000 stock options. These paired transactions relate to a board-approved option repricing, leaving him with 152,503 derivative securities directly owned after the changes.

How many options does Iveda Solutions CFO Robert Brilon hold after the repricing?

After the reported transactions, CFO Robert J. Brilon directly holds 152,503 derivative securities classified as options. This figure reflects the net position following the 125,000-option grant and the 125,000-option disposition tied to the board-approved repricing.

What was the new exercise price set in Iveda Solutions’ option repricing?

The option repricing approved by Iveda Solutions’ board set the exercise price of Robert Brilon’s options at $0.29 per share. According to the filing footnote, all other terms of the options remained unchanged as part of this repricing action.

Were the Iveda Solutions insider option transactions cash purchases or sales?

The transactions involve options recorded at a price of $0.00 per option and relate to an option repricing, not open-market cash purchases or sales. The filing characterizes them as a grant/award acquisition and a disposition to the issuer of derivative securities.

Why were the Iveda Solutions option transactions described as exempt?

The filing states the option repricing transactions were exempt under Rule 16b-6(d) and Rule 16b-3 of the Exchange Act. These exemptions generally apply to certain issuer-related derivative adjustments and board-approved compensation actions involving insiders like executive officers.

What do the acquire and dispose codes mean in Iveda’s Form 4 for IVDA?

The Form 4 labels one option transaction as an acquisition (grant, award, or other acquisition) and the other as a disposition to the issuer. Together they describe a repricing adjustment of existing options rather than separate market-based buying or selling activity.